Brooklyn FI LLC acquired a new position in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 594,919 shares of the company's stock, valued at approximately $677,000. Brooklyn FI LLC owned about 0.85% of SELLAS Life Sciences Group at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Anson Funds Management LP boosted its stake in SELLAS Life Sciences Group by 50.2% during the fourth quarter. Anson Funds Management LP now owns 1,192,266 shares of the company's stock worth $1,240,000 after acquiring an additional 398,431 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of SELLAS Life Sciences Group by 21.2% during the fourth quarter. Geode Capital Management LLC now owns 733,546 shares of the company's stock valued at $763,000 after purchasing an additional 128,355 shares during the period. Opus Capital Group LLC boosted its position in shares of SELLAS Life Sciences Group by 5.5% during the 4th quarter. Opus Capital Group LLC now owns 238,500 shares of the company's stock worth $248,000 after purchasing an additional 12,400 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of SELLAS Life Sciences Group by 33.6% during the 4th quarter. Northern Trust Corp now owns 134,721 shares of the company's stock worth $140,000 after purchasing an additional 33,878 shares in the last quarter. 17.38% of the stock is owned by institutional investors and hedge funds.
SELLAS Life Sciences Group Trading Down 1.2%
SELLAS Life Sciences Group stock traded down $0.02 during midday trading on Friday, reaching $1.69. The stock had a trading volume of 2,659,748 shares, compared to its average volume of 1,532,409. The company has a fifty day moving average price of $1.42 and a two-hundred day moving average price of $1.24. SELLAS Life Sciences Group, Inc. has a 12 month low of $0.77 and a 12 month high of $2.12. The company has a market capitalization of $168.62 million, a P/E ratio of -2.45 and a beta of 2.34.
SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. On average, equities research analysts predict that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current fiscal year.
SELLAS Life Sciences Group Profile
(
Free Report)
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Further Reading
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
